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Abstract: Clevidipine is a new calcium channel blocker of the dihydropyridine class that is 
characterized by its ultra-short onset of action, vascular selectivity, small volume of distribu-
tion and extremely high clearance that coupled together result in an extremely short half-life of 
approximately 1 minute therefore permitting a rapid titration to the desired effect. Structurally 
similar to other dihydropyridines, clevidipine has an extra ester link that allows its rapid 
hydrolization to its inactive carboxylic acid metabolite in blood and extravascular tissues. 
Clevidipine’s metabolites are then primarily eliminated through urine and fecal pathways. 
Clevidipine does not affect cytochrome P450 (CYP) enzymes and no clinically significant drug 
interactions have been determined. In trials like the ESCAPE trials, ECLIPSE, and VELOCITY, 
clevidipine demonstrated a significant improvement in the management of acute hypertension 
when compared to placebo as shown in both ESCAPE trials. The ECLIPSE trial compared 
clevidipine to other drugs currently used in the management of acute hypertension, such as 
sodium nitroprusside, nitroglycerine and nicardipine; clevidipine was superior to all three 
agents; in providing blood pressure support, safety and tolerability clevidipine also showed a 
significant reduction in mortality rate (4.7% vs 1.7%, P = 0.0445) when compared to sodium 
nitroprusside. In the VELOCITY trial clevidipine demonstrated a reduction in blood pressure 
of 6% at the 3 minute mark, 15% within 9.5 minutes and 27% at the 18 hour mark.
Keywords: clevidipine, calcium channel blockers, hypertensive crisis, hypertensive emergency, 
hypertensive urgency
Introduction to the management  
of acute hypertension
Chronic hypertension is among the most common medical conditions, affecting 
approximately 72 million people, which accounts to almost 30% of the population older 
than 20 years in the United States alone.1 Even though the chronic form of hyperten-
sion is by far the most common, it is the acute form of hypertension that presents a far 
greater challenge, with more and more frequent and severe complications and poorer 
short-term prognosis than chronic hypertension. Acute elevations in blood pressure 
(BP) may result in severe clinical conditions such as hypertensive encephalopathy, 
acute aortic dissection, acute myocardial infarction, acute renal failure, intracranial 
hemorrhage, acute heart failure, and eclampsia, among others.2
Hypertensive crises are most commonly encountered by emergency department 
(ED) personnel in a clinical setting, occurring in up to 27.5% of all nonsurgical 
emergencies presenting to the ED and accounting to up to 3% of all emergency 
room visits.3Therapeutics and Clinical Risk Management 2009:5 628
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Some of the most commonly used agents are intravenous 
short-acting vasodilators like sodium nitroprusside and 
nitroglycerin. Both are used in the management of acute 
hypertension due to high vascular resistance; however, both 
of these agents present multiple adverse effects that hinder 
their utility.4–7
Clevidipine is a relatively new, ultra-short acting, 
dihydropyridine, calcium channel blocker.8 Clevidipine’s 
effectiveness is due, in part, to its selectivity for arteriolar 
dilatation without affecting myocardial contractility and its 
lack of effect on venous capacitance.9 Characteristics like 
rapid onset of effect, high clearance, and small volume of 
distribution make it a promising agent for the management 
of acute severe hypertension.10
The Seventh Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood 
Pressure11 defined a ‘hypertensive emergency’ as an acute 
elevation in systolic blood pressure (SBP) and diastolic blood 
pressure (DBP) associated with end-organ damage; while an 
acute elevation of SBP and/or DBP without end-organ dam-
age can be defined as a ‘hypertensive urgency’.11
The swift differentiation between a hypertensive emer-
gency and hypertensive urgency is extremely important in the 
clinical settings, as the presence or lack of end-organ damage 
will dictate the urgency and aggressiveness of treatment. In a 
hypertensive emergency, the rapid reduction and control of 
BP is essential to avoid further end-organ damage,11 while in 
a hypertensive urgency the BP control can be achieved within 
the first 24 to 48 hours after its presentation, with minimal 
or no change in outcome.12,13
It is estimated that approximately 1% of chronically hyper-
tensive patients will experience a hypertensive crisis in their 
lifetime.14 Risk factors for hypertensive crises are similar to 
chronic hypertension, including old age, male gender, African 
American race, tobacco use, obesity, and diabetes mellitus.15,16 
The morbidity and mortality of hypertensive crises is directly 
dependent on the degree of target organ damage, adequate 
BP control, and adherence to treatment. In patients who do 
not receive medical treatment the mortality rate at 1 year can 
be as high as 79%17 and among all patients who present a 
hypertensive crises, there is a 5-year survival rate of 74%.18
Clinical assessment and initial 
management of acute hypertension
Patients who present to the ED with a hypertensive emergency 
will usually have a complaint that is directly related to the 
presence and degree of end-organ damage; most commonly 
chest pain, dyspnea and altered mental status.3
Patients who present to the ED with a hypertensive 
emergency need an immediate reduction in BP to reduce the 
risk and/or progression of end-organ damage; a general goal 
is the reduction of mean arterial pressure (MAP) by 15% to 
20% within the first 2 hours of initial evaluation. This is in 
contrast to hypertensive urgencies where there is no need for a 
rapid reduction in BP, and the target BP can be achieved over 
a period of 24 to 48 hours.19 In fact, unnecessary rapid reduc-
tion is not without risk, and correction of severely elevated 
BP can markedly reduce perfusion, causing ischemia and 
infarction, and may be associated with significant morbidity 
in hypertensive urgency.20–24 Although BP must be reduced 
in these patients, it must be lowered in a slow and controlled 
fashion to prevent organ hypoperfusion.
Hypertensive crisis in the surgical setting is an extremely 
common occurrence, affecting up to 25% of all patients 
that undergo surgery;25 it is particularly common during 
cardiac surgery, major vascular surgery (ie, carotid end-
arterectomy, aortic surgery), neurosurgery, head and neck 
surgery, renal transplantation, and major trauma, eg, burns or 
head injury). Postoperative hypertension (BP  190 mmHg 
and/or diastolic BP 100 mmHg on two consecutive readings 
after surgery)26,27 could result in creating significant adverse 
sequelae in both cardiac and noncardiac patients. Depending 
on the population examined, the incidence of postoperative 
hypertensive crises varies from 4% to 35% of patients shortly 
after a surgical procedure.28–30 Greater attention should be 
given to precise perioperative BP control, as excursions 
outside a targeted BP range have correlated with increased 
risk of 30-day mortality31 and increased odds ratio for post-
operative death to 3.8.25
Among the numerous agents currently utilized for the treat-
ment of acute hypertension none have the ideal combination 
of vascular selectivity, rapid onset and offset of action coupled 
with a low incidence of side effects. Nitroprusside has long 
been among the most utilized agents for rapid BP control. 
A short-acting intravenous vasodilator with well demon-
strated efficacy, nitroprussides utility is limited due to several 
disadvantages that include low arteriolar selectivity, toxicity, 
and side effects such as tachyphylaxis, reflex tachycardia, 
and rebound hypertension.32 An alternative vasodilator, 
nitroglycerin is not an ideal agent for first-line treatment due to 
lower efficacy than nitroprusside, fairly common occurrence 
of hypotension, tachyphylaxis, and reflex tachycardia.1,17,19
Another group of medications currently available for 
acute BP control is calcium channel blockers, particularly 
those of the dihydropyridine class. These agents have a 
demonstrated efficacy and vascular selectivity.Therapeutics and Clinical Risk Management 2009:5 629
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Review of pharmacology 
of clevidipine
Clevidipine is the latest generation calcium channel blocker 
of the dihydropyridine family, with characteristics of arterial 
selectivity, extremely rapid onset of action and high rate of 
clearance (see Table 1 and Figure 1).9,33–35
Clevidipine comes in a lipid emulsion, and the FDA 
recommends tube changes every 4 hours. There has been 
speculation that the clevidipine lipid emulsion may result 
in increased triglyceride levels. However, there have been 
no complications reported from the lipids. In the ECLIPSE 
trials the investigators stated that changes in triglyceride 
levels were similar for clevidipine and comparator agents.31 
Moreover, in the VELOCITY trial, long-term infusion of 
clevidipine lipid emulsion did not alter the median percent-
age change in triglyceride levels, and a post-hoc analysis 
demonstrated that there was no relationship between clevi-
dipine dose and change in triglyceride levels from baseline 
to 6 hours after clevidipine treatment.36
Pharmacokinetics
Clevidipine is structurally similar to other dihydropyridines; 
however an extra ester link allows its rapid hydrolization to 
its inactive carboxylic acid metabolite in blood and extra-
vascular tissues. Clevidipine’s metabolites are then primarily 
eliminated through urine and fecal pathways.34 Clevidipine 
has a very short half-life of approximately 1 minute10,35 
secondary to its high clearance (median blood clearance 
is 0.125 L/min/kg])35 and a small volume of distribution 
of 0.51 to 0.58 L/kg. These characteristics allow a more 
rapid titration to the desired effect, as the drug achieves 
steady blood concentrations rapidly after the initiation of 
an infusion,37,38 and a rapid decrease on BP effect after the 
infusion is suspended.8 After discontinuation or reduction of 
the infusion, in most patients, full recovery of BP is obtained 
in under 15 minutes.39
Clevidipine does not affect cytochrome P450 (CYP) 
enzymes and no clinically significant drug interactions have 
been determined39 increasing its margin of safety for drug 
interactions.
Pharmacodynamics
Clevidipine has an extremely rapid onset of effect in 2 to 
3 minutes.35 It exerts its effect by inhibiting transmembrane 
influx of calcium ions through the voltage-dependent L-type 
calcium channels.40 Like similar drugs of the dihydropyridine 
family, such as nicardipine and nifedipine, a key characteris-
tic of clevidipine is its arterial dilation selectivity. Vascular 
selectivity allows the decrease of BP by reducing vascular 
resistance but not causing venous dilation and therefore not 
affecting cardiac preload; thus it has minimal effect on stroke 
volume, cardiac output, or heart rate.41
A study of the pharmacokinetics and arteriovenous dif-
ferences in clevidipine concentration after a short- and a 
long-term intravenous infusion in healthy volunteers was 
performed by Ericsson et al42 In this study. The MAP and 
heart rate were monitored and recorded before (ie, baseline), 
during, and after short and 24-hour infusions of clevidipine. 
The MAP measurements after cessation of the 24-hour infu-
sion did not differ from those obtained at baseline, before 
starting of infusion. After short 20-minute infusion clevidip-
ine reduced MAP from approximately 90 to 75 mmHg, and 
increased heart rate from approximately 53 to 75 beats/min, 
at steady-state conditions. After cessation of the infusion, 
MAP and heart rate returned to predose measurements within 
10 minutes for all subjects.
Clevidipine trials
eSCAPe‑1
The Efficacy Study of Clevidipine Assessing Its Preoperative 
Antihypertensive Effect in Cardiac Surgery (ESCAPE-1) trial 
of 105 patients scheduled for cardiac surgery that were either 
diagnosed with hypertension or recently had hypertension, 
who were randomized into 2 groups. An intervention cohort 
received a 0.4 to 0.8 µg/kg/min infusion of clevidipine while 
the control group received an infusion of 20% lipid placebo 
emulsion. The clevidipine cohort had a significantly lower 
rate of treatment failure, defined as failure to reduce SBP 
by more than 15% from the baseline BP or the termination 
of infusion, when compared to placebo (7.5% vs 82.7%; 
P  0.0001). Of the patients who received clevidipine, 
90% reached the target BP at a median time of 6 minutes, 
Table 1 Pharmacology of clevidipine
Generalities
Class  Dihydropyridine
Pharmacokinetics
Metabolism  ester hydrolysis in blood
Metabolite  Inactive carboxylic metabolite H152/81
Plasma protein binding 99.5%
Volume of distribution 0.51–0.58 L/kg
Half‑life  Phase 1 = 1.6
Phase 2 = 15.5
Blood clearance  0.105 L/min/kgTherapeutics and Clinical Risk Management 2009:5 630
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while in the placebo group the median time was unable to 
be established because so few patients actually reached the 
target BP.33,43 The authors of ESCAPE-1 concluded that 
clevidipine was effective in quickly decreasing preoperative 
BP to targeted BP levels and was well tolerated in most 
patients.
In ESCAPE-1, clevidipine was shown to be well tolerated 
with an adverse event (AE) profile similar to that of placebo 
and consistent with outcomes expected in cardiac surgery.44,45 
A modest increase in heart rate was observed during clevi-
dipine administration, as has been reported with other intra-
venous dihydropyridines46,47 and in studies of clevidipine in 
essential hypertension and postcardiac surgery.10,32
A limitation of ESCAPE-1 was that it could not be 
designed to evaluate clevidipine during surgery for ethical 
reasons (ie, not treating hypertension), and therefore involved 
a somewhat artificial preoperative treatment strategy. 
Moreover, another potential study limitation was the influ-
ence of premedication on arterial BP. Because ESCAPE-1 
was designed as an acute assessment of antihypertensive 
treatment over 30 minutes, and included comparison of active 
treatment to placebo, it was unlikely that any effects of pre-
medication on study results would have gone unnoticed.
eSCAPe‑2
The Efficacy Study of Clevidipine Assessing Its Postoperative 
Antihypertensive Effect in Cardiac Surgery-2 (ESCAPE-2) 
is a double-placebo controlled trial that examined the safety 
and efficacy of clevidipine in post cardiac surgery patients 
with hypertension. The trial randomized 110 patients meeting 
the criteria for a diagnosis of postoperative hypertension into 
two groups; one received an infusion of clevidipine at 0.4 to 
0.8 µg/kg/min, while the second group received a 20% lipid 
emulsion for a maximum of 1 hour. The clevidipine group 
had a better success rate (91.8%; P  0.0001), defined as 
the absence of treatment failure, compared to placebo which 
had a success rate of 20.4%. Patients treated with clevidipine 
also showed a considerably greater reduction in mean arterial 
pressure than the placebo group 2 minutes after the infusion 
of either clevidipine or placebo (P = 0.0004). In the clevi-
dipine group there was a 5.7 mmHg reduction, compared 
to 0.1 mmHg with placebo. The efficacy of clevidipine was 
most evident when comparing the greatest mean change. 
The greatest mean change was 28.1 mmHg with clevidipine, 
compared to 8.9 mmHg for placebo (P  0.0001).48 AE rates 
were similar for both treatment groups with no clinically sig-
nificant increases in heart rate or acute adverse hemodynamic 
events. In the ESCAPE-2 trial, clevidipine was effective and 
safe in the rapid management of acute hypertension related 
to cardiac surgery.
VeLOCITY
The Prolonged Infusion of Clevidipine Results in Safe and 
Predictable Blood Pressure Control in Patients with Acute 
Severe Hypertension (VELOCITY) trial consisted of an 
open-label, single arm, multicenter study that enrolled 
126 patients that presented either to the emergency depart-
ment or intensive care unit with acute hypertension. The goal 
of VELOCITY was to ascertain the percentage of patients 
whose SBP decreased below a preset intended target after an 
initial dose of 2 mg/hour within a period of 3 minutes (safety 
endpoint, ie, overshoot rate), as well as the percentage of 
patients that reached an individualized target range within 
30 minutes (efficacy endpoint). In this trial, clevidipine 
showed a rapid and effective reduction in BP, with a decrease 
on average of 6%, corresponding to 12 mmHg within the 
3-minute time period, and a total reduction of 15% within 
9.5 minutes. The trial not only demonstrated clevidipine’s 
efficacy in the short term, but it also showed the efficacy of 
clevidipine with a longer-term infusion, as there was a 27% 
reduction in BP 18 hours after the initiation of the infusion 
(a reduction equivalent to 55 mmHg).36
In the VELOCITY safety population, 39.7% of patients 
experienced at least 1 AE after clevidipine initiation, and 
8.7% of patients experienced at least 1 serious AE. Head-
ache was the most frequently reported AE, with an overall 
incidence of 6.3% (8/126), followed by nausea (4.8%; 
6/126), chest discomfort (3.2%; 4/126), and vomiting (3.2%; 
4/126).
Patients in the safety population most often had AEs 
categorized by the investigator as mild (13.5%) or moderate 
(17.5%) in severity, as opposed to severe (8.7%). Safety 
patients most often had AEs assessed by the investigator 
as unrelated to clevidipine (30.2%) vs related (9.5%). Two 
of 126 patients complained of pruritus at the infusion site. 
The frequency of AEs, severity, and possible relationship 
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Figure 1 Structure of clevidipine.Therapeutics and Clinical Risk Management 2009:5 631
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to clevidipine were similar in the long-term cohort. The 
VELOCITY trial also ascertained that clevidipine is both 
safe and effective in patients with underlying severe 
hypertension, heart failure, or renal dysfunction. These data 
are compatible with data obtained from both ESCAPE trials. 
The authors concluded that clevidipine is a safe and effec-
tive drug in the rapid management of severe hypertension 
at a nonweight-based dose of 2 mg/hour followed by simple 
infusion titration to desired BP during 18 hours of more.
Limitations of the VELOCITY trial are that the trial was 
performed as an open-label uncontrolled study. However, 
it was designed to permit the use of concomitant intrave-
nous antihypertensive therapy at any time if needed; thus, 
each patient effectively served as his or her own control. 
The definition for severe hypertension used in this study 
(SBP  180 mmHg and/or DBP  115 mmHg) was 
developed according to clinical experience. No universally 
accepted definition exists for severe hypertension.17,49 The 
patient population studied represented a mixture of hyper-
tensive urgencies and emergencies. It is possible, therefore, 
that the patients without acute end-organ injury would not 
all have received intravenous antihypertensive therapy in 
routine clinical practice but would have been treated with 
oral antihypertensive agents.
VeLOCITY subset analyses
VELOCITY trial subset analyses have been performed in 
patients with renal dysfunction and acute heart failure. In 
subset of the Velocity trial, a safety and efficacy analysis 
of clevidipine used in 24 patients with moderate to severe 
renal dysfunction (50% on dialysis)50 found clevidipine 
rapidly and effectively lowered BP, was not associated with 
excessive or precipitous drops in BP, and had similar results 
in patients with or without renal dysfunction. Targeted BP 
control was rapidly achieved in 8.5 minutes and was main-
tained for the specified 18 hours duration after which most 
patients (88%) effectively transitioned to oral therapy within 
6 hours of clevidipine termination. In this high risk subpopu-
lation most AEs were assessed as unrelated to clevidipine 
treatment. This supports the relative safety of this product. 
The safety results of this subgroup analysis in patients with 
renal dysfunction are also consistent with the results of the 
overall VELOCITY trial.36
The safety and efficacy of clevidipine was also assessed 
in a VELOCITY subset analysis of patients with acute heart 
failure. In this group of 19 patients presenting with acute 
heart failure, the median time or treatment with clevidipine 
to a patient-specific prespecified initial target range (ITR) 
of SBP to be achieved within 30 minutes was 11.3 minutes. 
Most patients (94%) reached ITR within 30 minutes. No 
patient had hypotension below the ITR and heart rate 
remained stable. At 18 hours, 16/19 patients had received 
continuous clevidipine infusion and their SBP was reduced 
by mean of 50 mmHg (25%) from baseline. There were 
no treatment-related AEs, or AEs that led to clevidipine 
discontinuation. Likewise, the results of this subgroup analy-
sis in patients with acute heart failure are also consistent with 
the results of the overall VELOCITY trial.36
eCLIPSe
Lastly, the Evaluation of Clevidipine in the Periopera-
tive Treatment of Hypertension Assessing Safety Events 
(ECLIPSE) trial examined 1964 patients scheduled to 
undergo cardiac surgery that were randomized into 3 groups 
that would receive either clevidipine vs nicardipine, clevi-
dipine vs nitroglycerin, or clevidipine vs nitroprusside. Prior 
to surgical intervention, the patient’s BP was constantly 
monitored and study drug was administered as needed. 
‘Blood pressure excursions’ were defined as how long and 
how much the systolic BP was above or below individualized 
predetermined BP ranges.43 In all three analyses, clevidipine 
was superior to the comparator drugs in properly controlling 
BP, with almost half of the BP excursions in relation to the 
other agents (3.8 vs 7.8 mmHg × min/hour). Clevidipine also 
had the narrowest SBP range in pre- and postoperatively 
(105 to 145), and during surgery (93 to 135).
For specific comparisons, clevidipine had almost half the 
BP excursions vs nitroglycerin (4.14 vs 8.87 mmHg × min/
hour) and nitroprusside (4.37 vs 10.5 mmHg × min/hour). 
However, when clevidipine was compared to nicardipine, 
there was no significant difference in the pre/postop-
erative period in BP excursions (1.76 mmHg × min/hour vs 
1.79 mmHg × min/hour).43
Overall, clevidipine reduced BP to target in more than 
90% of patients with perioperative HTN.33,43 The ECLIPSE 
trial demonstrated that clevidipine not only has superior 
BP control than other drugs, but also showed a significant 
reduction in 30-day mortality rate compared to nitroprus-
side (4.7% vs 1.7%, P = 0.0445). There were no significant 
differences in incidence of cerebrovascular accident, heart 
attack, or kidney damage.43 The ECLIPSE trial is consistent 
with the ESCAPE 1 and 2 and VELOCITY trials showing 
that clevidipine is a safe and effective drug for the treatment 
of acute hypertension, but also demonstrated that clevidipine 
offers a more precise and titratable BP control than nitroprus-
side and nitroglycerin.Therapeutics and Clinical Risk Management 2009:5 632
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The incidence of the most commonly reported AEs, 
including atrial fibrillation and sinus tachycardia, were 
similar for clevidipine and the comparator drugs. Atrial 
fibrillation was reported as an AE at an incidence of 
33.6% vs 32.0% (clevidipine vs nitroglycerin); 36.1% vs 
32.2% (clevidipine vs sodium nitroprusside); and 35.6% 
vs 35.2% (clevidipine vs nicardipine), all P = NS. The 
incidences of serious AEs were similar among all groups. 
Clinical laboratory data including change in triglyceride 
levels were similar between clevidipine and the comparator 
drugs. In this trial, clevidipine administration did not cause 
an increase in triglyceride levels.
Limitations of the study include the open-label design. 
Moreover, clevidipine was dosed in a standard fashion at 
all study sites, while comparator drugs were administered 
according to institutional practice.
Clevidipine dosing and titrating
Clevidipine is easy to use and is initiated with a nonweight-
based starting dose followed by titration to a target BP. 
It may be administered as loading dose of 1 to 2 mg, 
followed by repeated incremental doubling of the dose at 
90-second intervals until the desired BP is achieved. As 
the BP approaches goal, the dose should be increased by 
less than double and the time between dose adjustments 
lengthened to every 5 to 10 minutes. An increase of approxi-
mately 1 to 2 mg/hour will generally produce an additional 
2 to 4 mmHg decrease in SBP. The desired therapeutic 
response for most patients occurs at doses of 4 to 6 mg/hour. 
Patients with severe hypertension may require doses up to 
32 mg/hour.39 Clevidipine is safe to administer by either 
central or peripheral line, providing convenience and flex-
ibility. When treatment with clevidipine is no longer required, 
patients can be easily and successfully transitioned to oral 
therapy (see Table 2).
Safety and tolerability
The ESCAPE, ECLIPSE and VELOCITY trials demon-
strated that clevidipine is a safe and tolerable drug with few 
adverse effects. The ESCAPE-1 and -2 trials showed that 
the most common and severe adverse effect was a slight 
increase in heart rate without clinical significance. Likewise, 
the VELOCITY trial reported no serious AEs attributable to 
clevidipine, including rebound hypertension. Finally, in the 
ECLIPSE trial there were no differences in death or adverse 
outcomes at the time of hospital discharge to day 7 among any 
of the treatment groups. Across all pivotal studies, it has been 
determined that clevidipine is a safe and effective treatment 
for patients with severe hypertension, those scheduled for 
cardiac surgery, those with acute hypertension undergoing 
cardiac surgery, and in the rapid treatment of acute postop-
erative hypertension after cardiac surgery.33,36,43,48
Patient-focused perspectives
The use of clevidipine is complicated by remarkably few 
side effects compared to other medications commonly 
used to treat these conditions. Despite its arterial selective 
vasodilation effects, clevidipine use has relatively little 
association with cephalgia. While nitroglycerin use in the 
ED commonly requires the coadministration of intravenous 
narcotics for intractable headache, this is much less common 
with clevidipine.
Clevidipine use has occasionally been reported to be 
associated with thrombophlebitis; however as reported in the 
package insert, this occurs at a rate approximating 1%, and 
as such may be considered a relatively rare side effect.39
An important consideration of the use of clevidipine is 
the potential for interaction with other agents. Because of its 
very short half-life, and its unique metabolic pathway that 
does not require hepatic or renal function, interactions are 
generally limited, and if occur can be terminated rapidly. 
Consideration for the potential of beta blocker withdrawal 
should be evaluated in patients on long-term beta blockers, 
who have them withheld while on clevidipine and develop 
unexplained tachycardia.
Because clevidipine is formulated within a 20% fat emul-
sion (0.2 g/mL) some attention to total lipid administration 
during a 24-hour period should be given. In conditions where 
there is significantly impaired lipid metabolism (eg, severe 
hyperlipidemia) or pathology that may potentially be wors-
ened by the increase in lipid load (eg, acute pancreatitis), 
clevidipine use should be monitored.
Limitations
The paper reviews the use parenteral clevidipine for the acute 
control of BP in the critically ill patient, and in particular, 
reviews the results of pivotal clevidipine trials. Therefore, 
the paper is limited to reviewing the data originally presented 
Table 2 Frequency of adverse effects
Adverse effect Frequency
Flushing 40%
Fever 18.9%
Atrial fibrillation 13.2%
Acute renal failure 9.4%
Nausea 5.7%Therapeutics and Clinical Risk Management 2009:5 633
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in the published manuscripts of each trial and the approved 
prescribing information. No additional or new data are 
provided.
Conclusion
With its extremely fast onset and offset of action and arterio-
lar selectivity, as well as its high effectiveness, ease of use, 
and dosing, clevidipine is a very promising new agent in the 
management of acute hypertension. Clevidipine is structur-
ally similar to other dihydropyridines; however it contains an 
extra ester link that allows the rapid hydrolization in blood 
and extravascular tissues. Since clevidipine is a pure after-
load reducer, it does not affect central venous pressure and 
therefore does not affect preload and cardiac output. Trials 
like ESCAPE, ECLIPSE, and VELOCITY have shown that 
clevidipine is a very safe, tolerable, and effective in patients 
with severe hypertension, heart failure, or renal dysfunction. 
In addition, clevidipine is easy to use and monitor via BP 
cuff, reducing the need for more invasive monitoring. These 
characteristics, coupled with its small volume of distribution, 
result in the rapid and easy titration to the desired effect.
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